Inclusion Criteria:

1. Histologic proof of prostate adenocarcinoma

2. Androgen-Dependent Prostate Cancer

3. Metastatic disease on bone scan and/or involvement of soft tissues (lymph nodes
and/or viscera) by computed tomography (CT) scan and/or magnetic resonance imaging
(MRI)

4. PSA > 1 ng/ml

5. Life expectancy from a co-morbid illness > 3 years

6. Eastern Cooperative Oncology Group (ECOG) performance status
7. Patients must have adequate organ function as defined by: Absolute Neutrophil Count
(ANC) >/= 1,500/ul (without colony stimulating factor support); Hemoglobin (Hgb) >/=
9 gm/dL; Total bilirubin with known Gilbert's disease, total bilirubin should be >/= 100,000/mm^3; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
< 1.5 x the upper limit of normal; Urine protein/creatinine ratio (UPCR) phosphorus >/= lower limits of normal (LLN); estimated creatinine clearance of >/=40
ml/min.

8. Patients already on Androgen Deprivation Therapy (ADT) are eligible as long as the
time from initiation of luteinizing hormone-releasing hormone (LHRH) analog or
antagonist is not greater than 1 month.

9. Prior ADT is allowed if it was an adjunct to definite local therapy, was given for
metastatic diseases

10. Prior therapy with other tyrosine kinase inhibitors (TKI) inhibitors or any other
type of investigational agent is allowed if it was an adjunct to definitive local
therapy, was given for initiating therapy for metastatic disease.

11. Patients with "anaplastic" features are eligible for this trial.

12. Sexually active fertile subjects, and their partners, must agree to use medically
accepted methods of contraception (eg, barrier methods, including male condom, female
condom, or diaphragm with spermicidal gel) during the course of the study and for 4
months after the last dose of study drug(s).

Exclusion Criteria:

1. Biological agents (antibodies, immune modulators, cytokines, or vaccines) or
radionuclide treatment within 6 weeks of the first dose of study treatment.

2. Radiation therapy within 2 weeks prior to initiation of study treatment.

3. Symptomatic or uncontrolled brain metastasis or epidural disease requiring current
treatment including steroids and anti-convulsant.

4. The subject has had another diagnosis of malignancy requiring systemic treatment
within the last two years, unless non-melanoma skin cancer, or superficial bladder
cancer.

5. The subject has prothrombin time (PT)/ International Normalized Ratio (INR) or
partial thromboplastin time (PTT) test results at screening >/= 1.3 x the laboratory
ULN.

6. The subject requires concomitant treatment, in therapeutic doses, with anticoagulants
such as warfarin or Coumadin-related agents, heparin, thrombin or Factor Xa (FXa)
inhibitors, and antiplatelet agents (eg, clopidogrel). Low dose aspirin ( mg/day), low-dose warfarin ( Heparin (LMWH) are permitted.

7. The subject has uncontrolled or significant intercurrent illness including, but not
limited to, the following conditions: Cardiovascular disorders such as symptomatic
congestive heart failure (CHF), uncontrolled hypertension defined as sustained blood
pressure (BP) > 140 mm mercury (Hg) systolic, or > 90 mm Hg diastolic despite optimal
antihypertensive treatment (BP must be controlled at screening), unstable angina
pectoris, clinically-significant cardiac arrhythmias, history of stroke (including
transient ischemic attack [TIA], or other ischemic event) within 6 months of study
treatment, myocardial infarction within 6 months of study treatment, history of
thromboembolic event requiring therapeutic anticoagulation within 6 months of study
treatment or main portal vein or vena cava thrombosis or occlusion.;Gastrointestinal
(GI) disorders particularly those associated with a high risk of perforation or
fistula formation including: Any of the following at the time of screening;

8. Continued from # 9) a) intra-abdominal tumor/metastases invading GI mucosa; b) active
peptic ulcer disease; c) inflammatory bowel disease (including ulcerative colitis and
Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or
appendicitis;Any of the following within 6 months before the first dose of study
treatment: a) history of abdominal fistula; b) gastrointestinal perforation; c) bowel
obstruction or gastric outlet obstruction; d) intra-abdominal abscess. Note: Complete
resolution of an intra-abdominal abscess must be confirmed prior to initiating
treatment with cabozantinib even if the abscess occurred more that 6 months ago.; GI
surgery (particularly when associated with delayed or incomplete healing) within 28
days. Note: Complete healing following abdominal surgery must be confirmed prior to
initiating treatment with cabozantinib even if surgery occurred more that 28 days
ago.

9. Continued from # 10) ;Other disorders associated with a high risk of fistula
formation including percutaneous endoscopic gastrostomy (PEG) tube placement within 3
months before the first dose of study therapy or concurrent evidence of intraluminal
tumor involving the trachea and esophagus.

10. The subject is unable to swallow capsules tablets

11. The subject has a previously-identified allergy or hypersensitivity to components of
the study treatment formulation.

12. Oral corticosteroids >/= 7.5mg/day prednisone (or prednisone equivalents).

13. Prior treatment with cabozantinib.

14. The subject has a corrected QT interval calculated by the Fridericia formula (QTcF)
>500 ms within 28 days before randomization.